Literature DB >> 28946191

TMEM88 inhibits extracellular matrix expression in keloid fibroblasts.

Huafei Zhao1, Fei Lu1, Shuo Cui1, Xinying Zhang1, Weixin Wang1, Enze Si1, Zhengjiang Yuan2.   

Abstract

Keloid is characterized by hyper-proliferation of fibroblasts and excess extracellular matrix (ECM) deposition. Transmembrane protein 88 (TMEM88), belonging to the TMEM family, was involved in the regulation of tumorigenesis and fibrogenesis. However, the role of TMEM88 in keloid formation remains unclear. This study aimed to investigate the effects of TMEM88 on keloid-derived fibroblasts (KFs) proliferation and ECM expression, and explore the underlying mechanism. Our results demonstrated that TMEM88 was lowly expressed in human keloid tissues and TGF-β1-stimulated KFs. TMEM88 overexpression significantly inhibited the proliferation and migration of KFs, as well as suppressed ECM expression in TGF-β1-stimulated KFs. Furthermore, TMEM88 overexpression greatly inhibited the protein levels of β-catenin, cyclin D1 and c-myc in TGF-β1-stimulated KFs. In conclusion, our data indicate that TMEM88 inhibits the TGF-β1-stimulated cell proliferation, migration and ECM expression in KFs through the inactivation of Wnt/β-catenin signaling pathway. Therefore, TMEM88 may be a potential therapeutic target for treating keloids.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Extracellular matrix (ECM); Keloid; TGF-β1; TMEM88

Mesh:

Substances:

Year:  2017        PMID: 28946191     DOI: 10.1016/j.biopha.2017.09.047

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

Review 1.  Biomechanical Regulatory Factors and Therapeutic Targets in Keloid Fibrosis.

Authors:  Fan Feng; Mingying Liu; Lianhong Pan; Jiaqin Wu; Chunli Wang; Li Yang; Wanqian Liu; Wei Xu; Mingxing Lei
Journal:  Front Pharmacol       Date:  2022-05-09       Impact factor: 5.988

2.  TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma.

Authors:  Jicheng Duan; Youwen Qian; Xiaohui Fu; Meiling Chen; Kai Liu; Hu Liu; Jiahe Yang; Chen Liu; Yanxin Chang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

3.  Bioinformatics study on different gene expression profiles of fibroblasts and vascular endothelial cells in keloids.

Authors:  Weihan Zheng; Guojian Lin; Zhizhou Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

4.  Retracted Article: TMEM88 inhibits fibrosis in renal proximal tubular epithelial cells by suppressing the transforming growth factor-β1/Smad signaling pathway.

Authors:  Huicong Li; Yunqian Wang; Baoping Chen; Jun Shi
Journal:  RSC Adv       Date:  2019-02-28       Impact factor: 4.036

Review 5.  Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors.

Authors:  Ming Cai; Wei-Jian Ni; Ying-Hong Wang; Jing-Ji Wang; Hong Zhou
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

6.  MicroRNA-708 modulates Hepatic Stellate Cells activation and enhances extracellular matrix accumulation via direct targeting TMEM88.

Authors:  Tao Xu; Linxin Pan; Liangyun Li; Shuang Hu; Hong Zhou; Chenchen Yang; Junfa Yang; Haodong Li; Yuming Liu; Xiaoming Meng; Jun Li
Journal:  J Cell Mol Med       Date:  2020-05-28       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.